Introduction
Chemotherapy with AZT ( Fig. 1, compound 1 ) in patients presenting with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) prolongs their survival, and reduces the incidence of opportunistic infections (Armstrong et aI., 1985; Yarchoan et aI., 1986) . AZT, 2' ,3'-dideoxycytidine (ddCyd) (Fig. 1, compound 2) and an increasing number of nucleoside analogues all act by inhibition of the HIV reverse transcriptase (Smith and Gallo, 1974; Mitsuya et aI., 1985; Mitsuya and Broder, 1986) , where the mode of action is chain termination and/or enzyme inhibition (Furman et al., 1986) . These nucleoside analogues become active following metabolic conversion to their5'-triphosphates (Cooney et aI., 1986) , but they may be poorly phosphorylated by cellular enzymes, a feature of their biochemistry which may reduce their clinical effectiveness (Furman et al., 1979; York and LePage, 1966) . Furthermore, amino nucleosides, such as ddCyd, are subject to metabolic deamination, a conversion which often brings about a diminution of their biological activity (Bryson and Connor, 1976; Haskell, 1977) . Most nucleoside analogues are also subject to phosphorylase-induced deactivation via glycosidic bond cleavage (Birnie et aI., 1963) .
Theoretically, all of these problems could be overcome by the use of the preformed 5'-phosphates of the bloactive nucleoside analogues (Heidelberger et al., 1960) , such as AZT 5'-monophosphate (AZTMP). In fact, little clinical advantage is seen on using nucleotides in place of nucleosides. This is mainly attributed to the poor membrane penetration by the (charged) nucleotides (lichtenstein et aI., 1960; Posternak, 1974) . Thus, uncharged phosphate triester derivatives of several chemotherapeutic nucleosides have been investigated as membranesoluble pro-drug forms (Chawla et al., 1984; Hunston et al., 1984; Farquhar and Smith, 1985; McGuigan et el., 1989) .
In this study, the application of these strategies to the potent anti-HIV compound AZT is presented. In particular, a phosphate-protecting group was sought which might be cleaved more rapidly in the HIV-infected cell; the resulting concentration of AZT nucleotides in the infected cell may enhance the antiviral selectivity. More specifically, the possibility of HIV protease (Navia et al., 1989 ) -induced cleavage of an oligopeptide from the phosphate moiety of an AZT phosphate triester would be a major step in drug design. As an initial study, we pursued the synthesis of simple triesters (Fig. 1, compound 3) of AZTMP, bearing an alkyl chain and a single N-linked, carboxyl-protected amino acid. This report describes the potent anti-HIV activity of these simple derivatives.
Results
The novel nucleoside phosphate triester derivatives were prepared by the reaction of unprotected nucleosides with novel alkyl amino acyl phosphorochloridates, of general formula' MeOC{O)CHRNH{R'O)POCI [R=H, Me, iPr, CH 2iPr, CHMe{Et), Bzl; R'=Me, Et, nPr, nBu, nHex] . The synthesis of these reagents involved the reaction of the appropriate carboxyl-protected amino acids with the alkyl In comparison with simple dial!<yl phosphate derivatives of AZT, the novel phosphoramidates reported here display potent anti-HIV activity. Clearly, the introduction of a P-N link is important. Indeed, relatively minor modifications in the amino acid moiety of (3a-j) lead to marked changes in activity. Substituting alanine (3a) by valine (3b), glycine (3c) or phenylalanine (3f) led to little change in activity (ED so c.
3-10 J.1M). However, substitution by leucine (3d), and especially isoleucine (3e), led to a substantial reduction in activity. Excluding the phenylalanine compound, there appears to be a diminishing activity with increasing steric bulk of the amino acid side chain. This suggests the possibility of enzymic cleavage of the amino acid moiety as an important step in the metabolic activation of these triesters; perhaps the unexpectedly high activity of the phenylalanine example represents favourable hydrophobic interactions with the putative hydrolysing enzyme.
Discussion
In every case the products were isolated as mixtures of diastereoisomers, this isomerism resulting from the combined multiple chiral centres. The presence of such isomers was always evident from spectroscopic data. For example, all but two of the compounds (3a-j) displayed two distinct resonances, each in the 31p NMR, with separations in the range 0.1-0.3 p.p.m. The signals were coincident in the cases of (3c) and (3f). The phosphorus chemical shifts were c. 8-9 p.p.m., as expected for dialkyl amino phosphates. (Mark et sl., 1969) . The presence of diastereoisomers was also evident in every case from 1H and 13C NMR data, where many ofthe peaks were split and in the same ratios as the 31p NMR peaks. 13C NMR chemical shifts and assignments for (3a-j) are listed in Table 1 , with full details for (3b) in Table 2 .
The diastereoisomers could be partially separated by simple 'flash' column chromatography. For example, in the case of (3j)three separate fractions (fast, medium and slow) were collected, and characterized and tested separately. In this case the partial separation was evident from . the changing ratios (1: 5 to 3: 2) of the two 31 P NMR signals. As we discuss below, it is possible that the two diastereoisomers of a given product might have widely differing biological activities.
The results for the anti-HIV activities of these derivatives are listed in Table 3 . Figure 2c shows the percentage inhibition of HIV-1 in a full titration by compound (3g) (mean data of five assays).
Also tested were a series of simple, symmetrical dialkyl phosphate derivatives of AZT (McGuigan et aI., 1990) , and a derivative of thymidine analogous to the above series ( Fig. 1, compound 4) . These compounds displayed no anti-HIV activity at the highest concentration studied, 100J.1M. Table 3 .
(I)
phosphorodichloridate R'OPOCI 2 , by standard procedures (Van Boom et ei.,~975). These reagents reacted cleanly but rather slowly with AZT in pyridine, but more rapidly using THF containing N-methylimidazole. The resulting derivatives (3a-j) were isolated, typically with c.
70-80% yield, after column chromatography, and were fully characterized by spectroscopic and analytical techniques.
HO
In contrast with the importance of the amino acid moiety, the alkyl group could be varied considerably without greatly affecting activity. Thus, lengthening the alkyl chain from methyl (3g) to ethyl (3b), propyl (3h), butyl (3i)and hexyl (3j)appeared to have no significant effect on activity.
The importance of the precise environment at phosphorus was supported by the stereochemical dependence of the biologial activity. In particular, the hexyl methoxyvalinyl compound (3D was tested as three separate fractions, as detailed above. It is notable that the 'slow' and 'medium' fractions have more marked anti-viral activity than the 'fast' fraction. Although the differences in activity are not great, it must be stressed that no fraction was one pure diastereoisomer, and so any differences in activity between the isomers will be diluted. Whether this stereochemical dependence applies to all of the compounds prepared and what stereochemistry leads to highest activity are not currently known.
The precise mechanism by which these derivatives exert their anti-HIV activity remains unclear. However, direct inhibition of HIV reverse transcriptase (Rl) has been excluded (F. Hamilton, Pfizer Central Research, Sandwich, UK, personal communication). Also, the Graph showing the percentage inhibition of HIV antigen for the phosphate triester (3g) for half-log dilutions from 0.01 to 10 fLM.The standard error for five assays is shown at each concentration. From this graph, the ED50 for the compound is given as 2.3 fLM.
derivatives seem completely stable to simple chemical hydrolysis under tissue culture conditions, further suggesting cell (or viral)-mediated hydrolysis. Lastly, the importance of having a bio-active nucleoside moiety was reinforced by the complete lack of activity of (4). However, this would be expected whether the triesters liberated AZT or AZTMP or a closely related derivative, but would not necessarily be expected if the triesters had anti-HIV activity in their own right.
In conclusion, asymmetrical phosphate triester derivatives of AZT bearing one .amino acid moiety possess marked anti-HIV activity in this assay system. Different amino acid groups confer changes in activity. The data indicate hydrolysis to a nucleotide derivative, via P-N cleavage, to be central to the activity of these compounds. However, the agent catalysing this breakdown in vitro remains unclear.
Materials and Experimental procedures: chemistry
All reactions were carried out under scrupulously dry conditions unless otherwise indicated. Reagents were dried as follows before use: triethylamine was distilled from CaH 2 , and pyridine and diethyl ether were distilled from CaH 2 onto activated 3A molecular sieves. THF was distilled from Na/benzophenone under nitrogen. N-methylimidazole was heated to 100°C over CaH 2 for 4h, and then distilled at 15mmHg. Nucleosides were dried at c. 50°C/0.1 mmHg for several hours before use. For thin-layer chromatography, Merck 60 F 2 5 4 precoated silica plates were employed. For flash column chromatography, Woelm 32-63 silica was used. Proton NMR spectra were recorded on a Varian XL200 spectrometer operating at 200 MHz or a Varian VXR400 operating at 400MHz. 31p NMR spectra were obtained on these instruments, operating at 81 MHz and 162 MHz, respectively. 13C spectra were recorded on the latter instrument at 100 MHz. Proton spectra were referenced to tetramethylsilane (TMS) or sodium 3-(trimethylsilyl)-1-propanesulphonic acid, phosphorus spectra to 85% phosphoric acid, and carbon spectra to CDCI 3; Et  10  3g  iPr  Me  3  3h  iPr  nPr  10  3i  iPr  nBu  3  3j iPr nHex 30,10,10'
Precise structures of phosphate triesters (3a-j) evaluated as inhibitors of HIV-1. In each case ED50 values are given, being the minimum concentrations of drug in J.LM which will reduce viral antigen production by 50%. a. ED50 values for the fast, medium and slow fractions of (3j), respectively (for full details see text).
positive shifts are downfield of the reference. All NMR spectra were recorded in CDCl s, unless otherwise stated. Microanalyses were performed at UCL, in the laboratory of Mr A. Stones; the phosphate triesters were noted to be hygroscopic, and analytical data are presented appropriately. The triesters were analysed by high performance liquid chromatography prior to biological evaluation (Gilson system, 5% water in MeCN On a 50 + 250mm
x 4.6 mm Sperisorb CN 5 fLM column, with a flow rate of 2 ml min", and detection by UV at 265 nm), and were free of AZT.
A standard procedure was used for all phosphorylating agents; a typical procedure is listed.
Ethyl methoxyalaninyl phosphorochloridate L-Alanine methyl ester (2.42g, 23.5mmol) in anhydrous diethyl ether (5ml) was added drop-wise with vigorous stirring to a solution of ethyl phosphorodichloridate (1.82 g, 11.2 mmol) in diethyl ether (10ml) at -40°C. The reaction mixture was allowed to warm to ambient temperature, with stirring for 3h, and then filtered. The filtrate was concentrated in vacuo, to give the product as a pale yellow oil (1.95g, 78%). 1l p +10.85, +10.97 (1: 1); 1l H 3.90 (2H,m,CH 20P), 3.75-3.80 (4H,m,OMe,CH*), 3.60 (1H,m,NH), 1.80 (3H,d,alanine Me), 1.30 (3H,t,CH sCH2).
A standard procedure was used for all nucleotide derivatives; a typical procedure is listed in full, and then simply departures from this for proceeding compounds.
3'-Azido-3'-deoxythymidine-5'-(ethyl methoxyalaninylj phosphate (3a)
3 f-Azido-3 f-deoxythymidine (1) (0.20g, 0.75mmol) and ethyl methoxyalaninyl phosphorochloridate (O.60g, 2.62mmol) were stirred together in anhydrous tetrahydrofuran (THF)(5ml) containing N-methylimidazole (0.42ml, 5.24mmol) for 48h, at ambient temperature. The solvent was removed in vacuo, and the residue dissolved in chloroform (30ml), and extracted with saturated sodium bicarbonate solution (10ml) and water (3 x 10ml). The organic phase was dried (MgS0 4 ) and evaporated in vacuo. The residue was redissolved in chloroform (10ml), and precipitated Novel phosphoramidates as anti-HIV drugs 111 with petroleum (bp 30-40°C) (400mI).The precipitate was purified by chromatography on silica gel (40g), using 4% methanol in chloroform as eluant. Pooling and evaporation of appropriate fractions gave the pure product (0.32g, 93% H 5.56, N 17.72, P 6.75; C1sH2sNsOaP.H20 requires C 40.17, H 5.69, N 17.57, P 6.47 . 1SC NMR data for this, and the other novel nucleotides, are presented in Table 1 .
3'-Azido-3'-deoxythymidine-5'-(ethyl methoxyvalinylj phosphate (3b)
Stirring was continued for only 18h, and the chromatographic column was eluted with 6% methanol in chloroform. Thus, from 0.26g of (1) was produced 0.32g (67%) of (3b). Bp +9.12, +9.26 H 6.17, N 16.84, P 6.33; C18N29NsOaP requires C 44.26, H 5.98, N 17.21, P 6.34 . Full 1sC NMR data for this compound are listed in Tables 1 and 2. 3'- Stirring was continued for only 16 h, and the chromatographic column was eluted with 5% methanol in chloroform. Thus, from 0.20g of (1) was produced 0.28g (84%) of (3c); Bp +9.12; 1l H (starred peaks are duplicated due to diastereoisomers) 8. 
3'-Azido-3'-deoxythymidine-5'-(ethyl methoxyleucinylj phosphate (3d)
Stirring was continued for only 24h. Thus, from 0.20g of (1) was produced 0.18g (52%) of (3d). Bp +8.52, +8.61 (3:4); 1l H (starred peaks are duplicated due to diastereoisomers) 9.40* (1H,s,NSH), 7.45* (1 H,s,H6), 6.25* (1H,t,H1 f) 1.90 (3H,s,5-Me), 1.75 (1H,m,leucine CH 2), 1.60 (1H,m,leucine CH 2), 1.50 (1H,m,iPr-CH), 1.30 (3H,m,CH sCH2), 0.90 (6H,d,leucine Me); Found C43. 12%, H 6.03, N 15.72, P5.45; C19Hs1NsOaP.[H20ks requires C 43.10, H 6.47, N 15.87, Stirring was continued for only 16 h, and the chromatographic column was eluted with 6% methanol in chloroform. Thus, from 0.15g of (1) was produced 0.18g (64%) of (3e). 3p +9.55, +9.69 (2: 3); 3 H (starred peaks are duplicated due to diastereoisomers) 8.90* (1H,s,N3H), 7.45* (1H,s,H6), 6.25* (1 H,t,H1'), 4.35* (1H,m,H4') , 4.05-4.25 (5H,m,H5',CH 20P,H3'), 3.80 (4H,m, isoleucine CH,OMe), 3.40 (1H,m,isoleucine NH), 2.45 (1H,m,H2'), 2.25 (tH,m,H2'), 2.00 (3H,s,5-Me), 1.80 (2H,m,isoleucine CH2), 1.40 (1H,m,isoleucine CH 3CH), 1.30 (3H,t,CH 3CH2), 0.90 (6H,m, isoleucine Me); Found C 43. 10%, H 6.27, N 16.23; C 19N31 N 60aP.[H20ks requires C 43.10, H 6.47, From 0.1Og of (1)was produced 0.11 g (55%) of (3f). 3p +8.65; 3 H (starred peaks are duplicated due to diastereoisomers) 9.70* (1H,s,N 3H), 7.35* (1H,s,H6), 7.10-7.35 (5H,m,Ph), 6.20* (1H,t,H1'), 4.30 (1H,m,H4'), 3.80-4.10 (5H,m,H5' ,CH 20P,H3'), 3.60-3.80 (5H,m,phenylalanine NH,CH,OMe), 3.10 (1H,d,phenylalanine CH 2), 2.90 (1H,d,phenylalanine CH 2), 2.40 (1H,m,H2'), 2.20(1H,m,H2'), 1.90 (3H,s,5-Me), 1.20 (3H,m,CH 3CH2); Found C 48.11 %, H 5.35, N 14.73; C22H29N60aP.H20 requires C 47.65, H 5.64, Stirring was continued for only 16h, and the chromatographic column was eluted with 5% methanol in chloroform. Thus, from 0.25g of (1) was produced 0.13g (30%) of (3g). 3p +8.12, +8.23 42.43%, H 5.78, N 17.14; C17H27N60aP.[H20]O.S requires C 42.24, H 5.84, Stirring was continued for only 16h. Thus, from 0.40g of (1) was produced 0.39g (52%) of(3h). s, +9.11, +9.33 (2: Found C 44.94%, H 6.19, N 16.51, P 6.21; C 19H31 N 60aP requires C 45.42, H 6.22, N 16 .73, P 6.16.
3'-Azido-3'-deoxythymidine-5'-(butyl methoxyvalinylj phosphate (3ij
Stirring was continued for only 16h. Thus, from 0.34g of (1) was produced 0.40g (61 %) of (3i). 3p +9.20, +9.39 (2:3); 3 H (starred peaks are duplicated due to diastereoisomers) 8.70* (1H,s,N 3H), 7.35* (1H,s,H6), 6.20* (1H,t,H1'), 4.30-4.40 (1H,m,H4'), 4.20 (2H,m,H5'), 4.00 (3H,m,CH 20P,H3'), 3.70 (4H,m,OMe,valine CH), 3.30 (1H,m,valine NH), 2.40 (1 H,m,H2'), 2.20 (1H,m,H2'), 2.00 (1H,m,iPr-CH), 1.90 (3H,s,5-Me), 1.60 (2H,m,CH 2CH20P), 1.35 (2H,m,CH 3CH2l, 0.80-1.00 (9H,m,CH3CH 2,valine Me); Found C 46. 29%, H 6.46, N 15.86, P 6.20; C2oH33N60aP requires C 46.51, H 6.44, N 16.27, P 6.00. 3 Stirring was continued for only 16 h and the chromatographic column was eluted with 5% methanol in chloroform, and the eluted product was collected as three separate fractions, on an arbitrary basis. Thus, from 0.44g of (1)was produced 0.50g (75%) of (3D, as three distinct fractions: 'fast', 'medium', and 'slow'. 3p +8.50, +8.80, ratios: 1 :5; 2:3; and 3:2, respectively; 3 H (mixed isomers, 1: 1; starred peaks are duplicated due to diastereoisomers) 8.55* (1H,s,N 3H), 7.40* (1H,s,H6 
Materials and Experimental procedures: virology

Biological evaluation
High titre virus stocks ofthe human immunodeficiency virus HIV-1 (RF strain of HTLV-III) were grown in H9 cells with RPMI-1640 (Flow Laboratories, Rickmansworth, Herts, UK) supplemented with 10% fetal calf serum, penicillin (100 IU 1-1 ) and streptomycin (100 fLg mr'), Cell debris was removed by low-speed centrifugation, and the supernatant stored at -70 DC until required. The target cell used in these assays was the C8166 CD4+ lymphoblastoid cell line. In a typical assay, C8166 cells were incubated with 10 TCID so HIV-1 at 3rC for 90 min and then washed three times with phosphate-buffered saline (PBSA, Dulbecco A). Cell aliquots (2 x 1oS) were resuspended in 1.5 ml growth medium in 6ml tubes, and compounds in half-log dilutions (100-0.1 f1M) were added immediately. The nucleoside phosphate triesters were sparingly soluble in aqueous solution, and 10mM stock solutions of each compound were made up in DMSO. The final DMSO concentration in the tissue culture medium was 1%. The cells were then incubated at 3rC in a 95% air/5% CO 2 incubator.
At 72 h post-infection, 200 fLl of supernatant were taken from each culture and assayed for HIV (Kinchington et al., 1989) using an antigen capture ELISA (Coulter, Luton, Beds, UK). The following controls were used: supernatants taken from uninfected, and infected cells, infected cells treated with AZT (Roche Products UK Ltd), and ddCyd (Roche Products UK Ltd, Welwyn Garden City, Herts, UK). The activities of AZT and ddCyd on infected cells consistently gave an ED so of c. 0.01 and 0.3 fLM, respectively (Fig. 2a ). The ELISA plates were read with a Bio-Rad spectrophotometer. Compounds were tested in duplicate at each concentration, and each compound was tested on at least two different occasions.
To test for compound toxicity, 2 x 10 5 aliquots of uninfected cells were cultured with the compounds in the same half-log dilutions for 72 h. The cells were then washed with PBSA and resuspended in 200fLi of growth medium containing 1 4C protein hydrolysate. After 12h the cells were harvested 'and the 14C incorporation measured (Fig. 2a,b) . Uninfected, untreated cells were used as controls. The compounds (3a-j) showed a range of activities (Table 3) , but none showed toxicity at 100 fLM in this system.
